secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193125-22-280741
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharma Q3 net loss $51.1M, NERD trial enrollment complete
-----------------------------------------------------------------

- Net loss of $51.1M in Q3 2022 vs. $36.7M in Q3 2021; R&D expense $19.0M, G&A $23.5M.
- Cash and equivalents $196.8M at Sep 30, 2022; additional $100M available under term loan.
- Completed enrollment in Phase 3 NERD daily dosing trial (776 patients); topline data expected Q1 2023.
- Secured up to $40M additional non-dilutive financing under revenue interest agreement; total capacity $300M.
- Planned Q1 2023 U.S. launches of VOQUEZNA TRIPLE PAK, DUAL PAK, and if approved, VOQUEZNA for EE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/0001193125-22-280741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/d412146d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-280741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer